We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Liquid Biopsy Device Selectively Captures Circulating Tumor Cells

By LabMedica International staff writers
Posted on 12 Aug 2019
A new type of antigen-independent liquid biopsy captures device exploits the preferential attachment of circulating tumor cells (CTCs) to the surface of carbon nanotubes.

The nanotube-CTC-chip is a novel 76-element microarray that combined carbon nanotube surfaces with microarray batch manufacturing techniques for the capture and isolation of tumor-derived epithelial cells.

Investigators at the Worcester Polytechnic Institute (MA, USA) and several other institutions collaborated to prepare the chips by using materials and batch fabrication techniques similar to those used to make semiconductors. More...
The current generation is configured as a 76-element array of test wells on a glass and silicon wafer. CTCs captured by the carbon nanotube chip remain viable and can be cultured. Furthermore, as the chips are transparent, it is possible to stain and study captured cells without removing them.

By combining lysis of red blood cells (RBC) with the carbon nanotube’s preferential adherence capabilities, the investigators demonstrated the capture and enrichment of CTCs with a five-log reduction of contaminating white blood cells (WBCs). Electron microscopy (EM) studies showed focal adhesion with filaments from the cell body to the nanotube surface.

The nanotube-CTC-chip successfully captured CTCs in the peripheral blood of breast cancer patients (stage 1–4) with a range of four to 238 CTCs per 8.5 millileters blood or 0.5–28 CTCs per milliliter. CTCs (based on CK8/18, Her2, and EGFR biomarkers) were successfully identified in seven out of seven breast cancer patients, and no CTCs were captured from two healthy controls. CTC enumeration based on multiple markers using the nanotube-CTC-chip enabled dynamic views of metastatic progression and could potentially have predictive capabilities for diagnosis and treatment response.

"Isolating CTCs with high purity is a significant challenge, akin to finding a needle in a haystack," said senior author Dr. Balaji Panchapakesan, professor of mechanical engineering at the Worchester Polytechnic Institute. "These cells comprise as few as one to 10 cells among a billion blood cells, and the shedding of CTCs from tumors is a highly discontinuous process."

"These initial clinical studies," said Dr. Panchapakesan, "in which we were able to capture and identify individual CTCs of varying phenotypes, show that this device could become an important tool not only for tracking the progression of cancers and their response to radiation or chemotherapy, but also in making predictions about the likely course of the cancer, which could help physicians identity the most effective course of therapy. This potentially life-saving technology could have multiple beneficial applications. It could help shed light on the complex biological and genetic processes at play in cancer. It could detect cancers at a very early stage by capturing the cells that nascent tumors shed into the blood. It could identify CTCs with metastatic potential before new tumors even begins, and it could help shape treatments customized to each person's cancer."

The nanotube-CTC-chip liquid biopsy device was described in the May 3, 2019, online edition of the journal Lab on a Chip.

Related Links:
Worcester Polytechnic Institute


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining Management Software
DakoLink
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.